GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle.
A new semimonthly treatment from Johnson & Johnson and ViiV Healthcare tamped down HIV as well as daily therapy in a midstage trial, promising a more convenient option for patients.
GlaxoSmithKline has struck a deal to trial its anti-OX40 monoclonal antibody in combination with Merck's Keytruda. The Phase I study is part of a slate of programs that GSK is hoping will support filings for up to 20 new drug approvals in the coming years, the success rate of which will go a long way to deciding whether the company can bounce back from its recent travails.
Pfizer admits it's wooing Allergan for a merger worth more than $100 billion. But what it's not saying publicly is that GlaxoSmithKline has rejected its advances. That's the word from the Financial Times, whose sources say Pfizer had been flirting with a GSK buy, but the U.K.-based drugmaker wasn't impressed. Pfizer duly backed away.
GlaxoSmithKline's respiratory unit is gearing up for a sunnier 2016--one that includes stellar coverage for its meds and a slowdown on Advair's price decline, CEO Andrew Witty said Wednesday. It's also ready to add a U.S. launch for new product Nucala to that list, and it'll find out soon whether it has the green light to do just that.
Drug R&D is a tough business. The odds are almost always against success, and the price to be paid for being wrong is cruelly high. That said, it did seem a little harder than usual this year to...
GlaxoSmithKline surpassed Wall Street's earnings estimates in Q3, with lower spending in vaccines and consumer health largely driving the beat. But that's not to say it didn't turn in a couple of standout sales performances.
Merck's Zostavax is the only shingles vaccine approved in the U.S. and EU, but it may not be for long. Based on results from two Phase III trials involving more than 16,000 older adults, GlaxoSmithKline plans to submit a regulatory filing for its shingles candidate, dubbed Shingrix, in North America, Japan and the EU in the second half of 2016.
The World Health Organization is throwing a roadblock in GlaxoSmithKline's plans to roll out its malaria vaccine, dubbed RTS,S or Mosquirix, by calling for the vaccine to be used in pilot projects before a widespread campaign. Such pilot projects can take up to 5 years to complete.
More than a year after its second big Phase III program for darapladib also turned out to be a bust, GlaxoSmithKline is reporting today that losmapimod--cited by CEO Andrew Witty as a top late-stage program--failed to measure up in the first leg of a clinical marathon. And it's not planning to fund step two.